| Name | Title | Contact Details |
|---|---|---|
Samuel Maeder |
Information Security Director | Profile |
Established in 1988, Health Design Plus (HDP) initially a Care Management company, expanded its suite of services to include network development/management and claims administration. With over 25 years of continued success, Health Design Plus continues to offer new products, such as Good Health by Design®, a suite of Wellness programs including LifeStart®, a Maternity Management program, Wellness Counts®, a biometric screening and coaching program, Carewise®, a Care Management program, and Healthy Living™, a Disease Management program, designed to fit all wellness-readiness levels, promoting healthier lifestyle choices and behavior modification to reach personal goals. Health Design Plus helps clients fuel their fiscal health in the marketplace while improving the health of their employees and members. Recently, HDP has gained national recognition as the industry leader in Domestic Travel Surgery programs with the launch of CliniFIT™ Centers of Excellence. HDP`s CliniFIT™ Centers of Excellence programs offer employers unparalleled commitment to consistently deliver safe, effective, evidence-based care. Qualified employees have access to recognized leaders in specific fields of medicine, Cardiac, Spine and Joint Replacement.
Toronto Academy of Dentistry is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quilleer and Blake Advertising is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Infinx Healthcare is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.